首页> 外国专利> PRODRUG FOR THE TREATMENT OF DISEASE AND INJURY OF OXIDATIVE STRESS

PRODRUG FOR THE TREATMENT OF DISEASE AND INJURY OF OXIDATIVE STRESS

机译:治疗疾病和氧化应激损伤的前药

摘要

The present invention includes a method for using diNACA as a prodrug to deliver diNACA, NACA and NAC to a mammal for therapeutic purposes to prevent or treat diseases or disorders involving oxidative stress. The method includes any disease that involves the therapeutic use of NACA or NAC as a therapeutic agent. Also, compositions and methods for the prevention, reduction or treatment of corneal endothelial cell loss in a patient that comprise providing the patient with an amount of at least one, alone or in combination, of N-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) (diNACA) to prevent or reduce the corneal endothelial cell loss or to prevent or treat presbyopia. DiNACA can be used to prevent or treat cataracts.
机译:本发明包括使用Dinaca作为前药的方法,以将Dinaca,NaCl和NaC递送至哺乳动物,以预防或治疗涉及氧化应激的疾病或病症。该方法包括任何涉及NaCA或NaC作为治疗剂的治疗用途的疾病。另外,用于预防,减少或治疗角膜内皮细胞损失的组合物和方法,其包括向患者提供至少一种,单独或组合的N-乙酰半胱氨酸酰胺(Naca)或(2R, 2R') - 3,3'-二磺酰基丙基双(2-乙酰氨基丙基甲酰胺)(Dinaca)(Dinaca)预防或减少角膜内皮细胞损失或预防或治疗老龄之症。 Dinaca可用于预防或治疗白内障。

著录项

  • 公开/公告号US2021228509A1

    专利类型

  • 公开/公告日2021-07-29

    原文格式PDF

  • 申请/专利权人 NACUITY PHARMACEUTICALS INC.;

    申请/专利号US202117156560

  • 发明设计人 G. MICHAEL WALL;

    申请日2021-01-23

  • 分类号A61K31/16;A61K9;A61P27/02;A61P39/06;

  • 国家 US

  • 入库时间 2022-08-24 20:14:44

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号